Peptide Receptor Radionuclide Therapy (PRRT) Market By Therapy Type (Somatostatin Receptor Antagonists, Radiolabeled Peptides), By Application (Neuroendocrine Tumors, Gastrointestinal Tumors, Lung Cancer), By End-User (Hospitals & Clinics, Cancer Treatment Centers, Research Institutions), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptide Receptor Radionuclide Therapy (PRRT) Market was valued at USD 2.5 billion in 2024-e and will surpass USD 4.1 billion by 2030; growing at a CAGR of 8.1% during 2025 - 2030.

The Peptide Receptor Radionuclide Therapy (PRRT) market is experiencing substantial growth, fueled by the increasing adoption of targeted cancer therapies. PRRT is a form of molecular therapy used to treat cancers that express certain receptors, such as neuroendocrine tumors. This therapy involves the use of radiolabeled peptides that bind to specific receptors on tumor cells, delivering targeted radiation directly to the cancer cells, minimizing damage to surrounding healthy tissues.

PRRT offers an innovative and effective treatment option for patients with tumors that are difficult to treat with conventional therapies like surgery or chemotherapy. The growing focus on personalized and precision medicine, combined with advancements in molecular imaging and radiopharmaceuticals, has led to the expansion of the PRRT market.

Radiolabeled Peptides Segment Holds the Largest Market Share

The radiolabeled peptides segment holds the largest market share within the PRRT market. This segment involves peptides that are tagged with radioactive isotopes, such as lutetium-177 or yttrium-90, which are delivered to tumors expressing specific receptors, such as somatostatin receptors. Radiolabeled peptides are particularly effective in targeting neuroendocrine tumors (NETs), a group of tumors that commonly express somatostatin receptors.

Radiolabeled peptide therapies like Lutathera, a treatment approved for neuroendocrine tumors, have gained significant traction due to their targeted approach and ability to provide long-term therapeutic benefits. The growing adoption of radiolabeled peptides in clinical settings is expected to drive the growth of this segment.

Neuroendocrine Tumors (NETs) Application Leads the Market

The neuroendocrine tumors (NETs) application segment is the largest and fastest-growing segment in the PRRT market. NETs are rare cancers that develop in neuroendocrine cells, which are found throughout the body. These tumors often express somatostatin receptors, making them an ideal target for peptide receptor radionuclide therapy.

PRRT has demonstrated significant efficacy in treating NETs, especially when conventional therapies like surgery or chemotherapy are not viable. The growing prevalence of NETs, along with the increasing number of approvals for radiolabeled peptide therapies, has led to the rapid expansion of the PRRT market for neuroendocrine tumors. With continued research and clinical trials, the market for NETs is expected to grow further in the coming years.

Hospitals & Clinics Segment is the Largest End-User

The hospitals and clinics segment is the largest end-user of PRRT, owing to their role as primary healthcare providers for cancer treatments. Hospitals and clinics have the infrastructure, expertise, and resources to deliver specialized therapies like PRRT. These settings are essential for administering radiolabeled peptide therapies, which require advanced medical equipment and a multidisciplinary team of healthcare professionals for patient management.

Additionally, hospitals and clinics are the main centers where patients are diagnosed and treated for conditions like neuroendocrine tumors, gastrointestinal tumors, and lung cancer. As the adoption of PRRT grows, hospitals and clinics will continue to play a crucial role in delivering this cutting-edge therapy to patients.

North America Leads the PRRT Market Due to Advanced Healthcare Systems

North America holds a dominant position in the peptide receptor radionuclide therapy market, driven by the region's advanced healthcare infrastructure, high prevalence of cancer, and significant investments in cancer research. The United States, in particular, is a major market for PRRT due to its leadership in oncology treatments and molecular medicine.

The region's strong research and development capabilities, coupled with growing approval rates for new radiolabeled peptide therapies, contribute to the market's growth. Additionally, the presence of well-established cancer treatment centers and a high rate of adoption of new therapies make North America a key player in the global PRRT market.

Competitive Landscape

The PRRT market is highly competitive, with several pharmaceutical and biotechnology companies actively involved in developing and commercializing radiolabeled peptide therapies. Companies are focusing on improving the efficacy of radiolabeled peptides, expanding their applications, and enhancing patient outcomes.

The market is characterized by strong research and development activities, with ongoing clinical trials aimed at exploring new combinations of radiolabeled peptides and targeted therapies. Strategic partnerships, mergers, and acquisitions are common as companies look to strengthen their product portfolios and expand their reach in the global market. The increasing interest in personalized medicine and targeted therapies will continue to drive innovation in the PRRT market, leading to new treatment options for patients with various types of cancer.

List of Leading Companies:

• Novartis
• Ipsen
• AAA/Endocyte (Eli Lilly and Company)
• Theragnostics
• Advanced Accelerator Applications (AAA)
• Siemens Healthineers
• GE Healthcare
• Bayer Healthcare
• Pfizer
• Medtronic
• Johnson & Johnson
• Bristol-Myers Squibb
• Merck & Co.
• Amgen Inc.
• Novocure

Recent Developments:

• In December 2024, Novartis launched a new peptide receptor radionuclide therapy for the treatment of advanced neuroendocrine tumors.
• In November 2024, Ipsen received approval for a new somatostatin receptor antagonist for PRRT in gastrointestinal cancers.
• In October 2024, Eli Lilly’s AAA/Endocyte introduced a new radiolabeled peptide therapy for lung cancer.
• In September 2024, Siemens Healthineers expanded its peptide receptor radionuclide therapy offering with a new diagnostic tool for cancer detection.
• In August 2024, GE Healthcare partnered with Novartis to develop targeted PRRT therapies for solid tumors.

Report Scope: